Goldman Sachs Report Questions Financial Sustainability of Curative Gene Therapies
Goldman Sachs warns sales from the most successful disease treatments are difficult to maintain.
Read the full articleYou might also wanna read
Manufacturing and regulatory hurdles threaten cell and gene therapy progress
What I’ve been reading (and watching) week ending 14 June 2026 Manufacturing requirements are killing cell and gene therapy Until manufactur
medium.com·1mo ago
High-cost gene therapies face financing barriers in US healthcare system
“We do not lack cures. We lack the infrastructure to pay for and deliver them,” writes William Padula.
statnews.com·1mo ago
Study Argues Sustainable Finance Has Failed to Address Climate Change
A new study by Lisa Sachs, director of the Columbia Center on Sustainable Investment, lays out the problem.
bloomberg.com·1mo ago
Navigating the Complex Landscape of Cell and Gene Therapy Manufacturing
Consultants from ProPharma express optimism about the trajectory of cell and gene therapy despite technical and logistical difficulties rema
Future of Long-Term Healthcare: Exploring the Potential of Regenerative Therapies
Regenerative therapies offer hope for treating previously intractable diseases and injuries by harnessing the body's natural healing mechani
New Lund model aims to shorten the path to life-saving cell and gene therapies
Despite groundbreaking research, many cell and gene therapies do not make it all the way to the patients. Researchers and clinicians in Lund
Comments
Sign in to join the conversation.
No comments yet. Be the first.